Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00620542
Registration number
NCT00620542
Ethics application status
Date submitted
6/02/2008
Date registered
21/02/2008
Date last updated
16/07/2012
Titles & IDs
Public title
CRESTOR Athero Imaging Head to Head IVUS Study
Query!
Scientific title
Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)
Query!
Secondary ID [1]
0
0
2007-004000-13
Query!
Secondary ID [2]
0
0
D356IC00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SATURN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Atherosclerosis
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Rosuvastatin
Treatment: Drugs - Atorvastatin
Experimental: Rosuvastatin 20 mg - Rosuvastatin 20 mg distributed in 2-week run-in period
Active comparator: Atorvastatin 40 mg - Atorvastatin 40 mg distributed in 2-week run-in period
Experimental: Rosuvastatin 40 mg - Rosuvastatin 40 mg distributed in core 2-year study
Active comparator: Atorvastatin 80 mg - Atorvastatin 80 mg distributed in core 2-year study
Treatment: Drugs: Rosuvastatin
capsule, oral, once daily
Treatment: Drugs: Atorvastatin
capsule, oral, one daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)
Query!
Assessment method [1]
0
0
Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as:
\[sum(EEMcsa-LUMENcsa)/sum EEMcsa\]\*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.
Query!
Timepoint [1]
0
0
End of study (Week 104)
Query!
Secondary outcome [1]
0
0
Numbers of Patients Showing Regression in PAV
Query!
Assessment method [1]
0
0
Regression defined as a change from baseline in PAV \< 0
Query!
Timepoint [1]
0
0
End of study (Week 104)
Query!
Secondary outcome [2]
0
0
Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)
Query!
Assessment method [2]
0
0
Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.
Query!
Timepoint [2]
0
0
End of study (Week 104)
Query!
Secondary outcome [3]
0
0
Numbers of Patients Showing Regression in TAV
Query!
Assessment method [3]
0
0
Regression defined as a change from baseline in TAV \< 0
Query!
Timepoint [3]
0
0
End of study (Week 104)
Query!
Secondary outcome [4]
0
0
Total Cholesterol Blood Level
Query!
Assessment method [4]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [4]
0
0
104 weeks
Query!
Secondary outcome [5]
0
0
LDL-C Blood Level
Query!
Assessment method [5]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [5]
0
0
104 weeks
Query!
Secondary outcome [6]
0
0
HDL-C Blood Level
Query!
Assessment method [6]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [6]
0
0
104 weeks
Query!
Secondary outcome [7]
0
0
Triglycerides Blood Level
Query!
Assessment method [7]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [7]
0
0
104 weeks
Query!
Secondary outcome [8]
0
0
Non-HDL-C Blood Level
Query!
Assessment method [8]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [8]
0
0
104 weeks
Query!
Secondary outcome [9]
0
0
LDL-C/HDL-C Blood Level
Query!
Assessment method [9]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [9]
0
0
104 weeks
Query!
Secondary outcome [10]
0
0
Total Cholesterol/HDL-C Blood Level
Query!
Assessment method [10]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [10]
0
0
104 weeks
Query!
Secondary outcome [11]
0
0
Non-HDL-C/HDL-C Blood Level
Query!
Assessment method [11]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [11]
0
0
104 weeks
Query!
Secondary outcome [12]
0
0
Apolipoprotein B Blood Level
Query!
Assessment method [12]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [12]
0
0
104 weeks
Query!
Secondary outcome [13]
0
0
Apolipoprotein A-1 Blood Level
Query!
Assessment method [13]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [13]
0
0
104 weeks
Query!
Secondary outcome [14]
0
0
Apoliprotein B/Apolipoprotein A-1 Blood Level
Query!
Assessment method [14]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [14]
0
0
104 weeks
Query!
Secondary outcome [15]
0
0
VLDL-C During the 104 Week Treatment Period
Query!
Assessment method [15]
0
0
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Query!
Timepoint [15]
0
0
104 weeks
Query!
Eligibility
Key inclusion criteria
* Clinical indication for coronary angiography
* Angiographic evidence of Coronary Artery Disease (CAD), as defined by at least 1 lesion in a native coronary artery that has >20% reduction in lumen diameter by visual estimation
* Left main coronary artery must have <=50% reduction in lumen diameter by visual estimation
* LDL-C >100 mg/dL (2.6 mmol/L) for patients with no statin therapy in the past 4 weeks; LDL-C >80mg/dL (2.08mmol/L) for patients on therapy in the past 4 weeks
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Use of certain lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis.
* Patients who have symptoms consistent with moderate or greater severity of Congestive Heart Failure (CHF).
* Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2333
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Query!
Recruitment hospital [1]
0
0
Research Site - Liverpool
Query!
Recruitment hospital [2]
0
0
Research Site - New Lambton Heights
Query!
Recruitment hospital [3]
0
0
Research Site - Chermside
Query!
Recruitment hospital [4]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [5]
0
0
Research Site - Perth
Query!
Recruitment postcode(s) [1]
0
0
- Liverpool
Query!
Recruitment postcode(s) [2]
0
0
- New Lambton Heights
Query!
Recruitment postcode(s) [3]
0
0
- Chermside
Query!
Recruitment postcode(s) [4]
0
0
- Adelaide
Query!
Recruitment postcode(s) [5]
0
0
- Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Minnesota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Montana
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Mexico
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
North Dakota
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Ohio
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oklahoma
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oregon
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Buenos Aires
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Santa Fe-argentina
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Cordoba
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Corrientes
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Aalst
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Brugge
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Brussels
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Charleroi
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Genk
Query!
Country [41]
0
0
Belgium
Query!
State/province [41]
0
0
Leuven
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
ES
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
GO
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
MG
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
MT
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
PR
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
SP
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Alberta
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
British Columbia
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Manitoba
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
New Brunswick
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Nova Scotia
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Ontario
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Quebec
Query!
Country [55]
0
0
Canada
Query!
State/province [55]
0
0
Saskatchewan
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Besancon
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Bron
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Creteil
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Le Plessis-robinson
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Marseille
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Pessac
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Quincy Sous Senart
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Strasbourg
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Toulouse
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Budapest
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Szged
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
AR
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Milano
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
MI
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
PR
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
SI
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
UD
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Novara
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Roma
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Jalisco
Query!
Country [76]
0
0
Mexico
Query!
State/province [76]
0
0
Aguascalientes
Query!
Country [77]
0
0
Mexico
Query!
State/province [77]
0
0
D.F
Query!
Country [78]
0
0
Mexico
Query!
State/province [78]
0
0
Monterrey
Query!
Country [79]
0
0
Mexico
Query!
State/province [79]
0
0
Puebla
Query!
Country [80]
0
0
Mexico
Query!
State/province [80]
0
0
Queretaro
Query!
Country [81]
0
0
Mexico
Query!
State/province [81]
0
0
Tijuana
Query!
Country [82]
0
0
Netherlands
Query!
State/province [82]
0
0
Alkmaar
Query!
Country [83]
0
0
Netherlands
Query!
State/province [83]
0
0
Amsterdam
Query!
Country [84]
0
0
Netherlands
Query!
State/province [84]
0
0
Breda
Query!
Country [85]
0
0
Netherlands
Query!
State/province [85]
0
0
Eindhoven
Query!
Country [86]
0
0
Netherlands
Query!
State/province [86]
0
0
Enschede
Query!
Country [87]
0
0
Netherlands
Query!
State/province [87]
0
0
Leeuwarden
Query!
Country [88]
0
0
Netherlands
Query!
State/province [88]
0
0
Nieuwegein
Query!
Country [89]
0
0
Netherlands
Query!
State/province [89]
0
0
Nijmegen
Query!
Country [90]
0
0
Netherlands
Query!
State/province [90]
0
0
Rotterdam
Query!
Country [91]
0
0
Netherlands
Query!
State/province [91]
0
0
Zwolle
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Bialystok
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Katowice
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Kedzierzyn Kozle
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Krakow
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Lodz
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Poznan
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Warszawa
Query!
Country [99]
0
0
Poland
Query!
State/province [99]
0
0
Zabrze
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Moscow Region
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Moscow
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Saint Petersburg
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Tomsk
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
Tumen
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Andalucia
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Asturias
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Cataluna
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Comunidad de Madrid
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Comunidad Valenciana
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
The Cleveland Clinic
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00620542
Query!
Trial related presentations / publications
Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC Cardiovasc Imaging. 2014 Oct;7(10):1013-22. doi: 10.1016/j.jcmg.2014.04.019. Epub 2014 Sep 17. Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Tuzcu EM, Nicholls SJ. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr;15(4):380-8. doi: 10.1093/ehjci/jet251. Epub 2014 Jan 20. Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013 Nov 26;128(22):2395-403. doi: 10.1161/CIRCULATIONAHA.113.004243. Epub 2013 Sep 16. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Stephen J Nicholls, MBBS, PhD
Query!
Address
0
0
Cleveland Clinic Foundation, Cardiovascular Medicine
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00620542
Download to PDF